NeuroMolecular Medicine

, Volume 13, Issue 2, pp 117–137 | Cite as

APP Transgenic Mice: Their Use and Limitations

Review Paper
First Online:
Received:
Accepted:

Abstract

Alzheimer’s disease is the most widespread form of dementia. Its histopathological hallmarks include vascular and extracellular β-amyloid (Aβ) deposition and intraneuronal neurofibrillary tangles (NFTs). Gradual decline of cognitive functions linked to progressive synaptic loss makes patients unable to store new information in the earlier stages of the pathology, later becoming completely dependent because they are unable to do even elementary daily life actions. Although more than a hundred years have passed since Alois Alzheimer described the first case of AD, and despite many years of intense research, there are still many crucial points to be discovered in the neuropathological pathway. The development of transgenic mouse models engineered with overexpression of the amyloid precursor protein carrying familial AD mutations has been extremely useful. Transgenic mice present the hallmarks of the pathology, and histological and behavioural examination supports the amyloid hypothesis. As in human AD, extracellular Aβ deposits surrounded by activated astrocytes and microglia are typical features, together with synaptic and cognitive defects. Although animal models have been widely used, they are still being continuously developed in order to recapitulate some missing aspects of the disease. For instance, AD therapeutic agents tested in transgenic mice gave encouraging results which, however, were very disappointing in clinical trials. Neuronal cell death and NFTs typical of AD are much harder to replicate in these mice, which thus offer a fundamental but still imperfect tool for understanding and solving dementia pathology.

Keywords

Alzheimer’s disease Transgenic mice Beta-amyloid Cognitive function Synaptic plasticity Brain imaging 
This is a preview of subscription content, log in to check access.

References

  1. Abraham, W. C., & Williams, J. M. (2008). LTP maintenance and its protein synthesis-dependence. Neurobiology of Learning and Memory, 89, 260–268.PubMedGoogle Scholar
  2. Aho, L., Pikkarainen, M., Hiltunen, M., et al. (2010). Immunohistochemical Visualization of Amyloid-beta Protein Precursor and Amyloid-beta in Extra- and Intracellular Compartments in the Human Brain. Journal of Alzheimer’s Disease, 20, 1015–1028.PubMedGoogle Scholar
  3. Akiyama, H., Barger, S., Barnum, S., et al. (2000). Inflammation and Alzheimer’s disease. Neurobiology of Aging, 21, 383–421.PubMedGoogle Scholar
  4. Almeida, C. G., Tampellini, D., Takahashi, R. H., et al. (2005). Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GLR1 in synapses. Neurobiology of Disease, 20, 187–198.PubMedGoogle Scholar
  5. Arendash, G. W., & King, D. L. (2002). Intra- and intertask relationships in a behavioral test battery given to Tg2576 transgenic mice and controls. Physiology & Behavior, 75, 643–652.Google Scholar
  6. Arendash, G. W., King, D. L., Gordon, M. N., et al. (2001). Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Research, 891, 42–53.PubMedGoogle Scholar
  7. Bacskai, B. J., Klunk, W. E., Mathis, C. A., et al. (2002). Imaging amyloid-beta deposits in vivo. Journal of Cerebral Blood Flow and Metabolism, 22, 1035–1041.PubMedGoogle Scholar
  8. Badea, A., Johnson, G. A., & Jankowsky, J. L. (2010). Remote sites of structural atrophy predict later amyloid formation in a mouse model of Alzheimer’s disease. Neuroimage, 50, 416–427.PubMedGoogle Scholar
  9. Balducci, C., Beeg, M., Stravalaci, M., et al. (2010a). Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proceedings of the National Academy of Sciences of the United States of America, 107, 2295–2300.PubMedGoogle Scholar
  10. Balducci, C., Tonini, R., Zianni, E., et al. (2010b). Cognitive deficits associated with alteration of synaptic metaplasticity precede plaque deposition in APP23 transgenic mice. Journal of Alzheimer’s Disease. (in press).Google Scholar
  11. Benveniste, H., Einstein, G., Kim, K. R., et al. (1999). Detection of neuritic plaques in Alzheimer’s disease by magnetic resonance microscopy. Proceedings of the National Academy of Sciences of the United States of America, 96, 14079–14084.PubMedGoogle Scholar
  12. Benveniste, H., Ma, Y., Dhawan, J., et al. (2007). Anatomical and functional phenotyping of mice models of Alzheimer’s disease by MR microscopy. Annals of the New York Academy of Sciences, 1097, 12–29.PubMedGoogle Scholar
  13. Bereiter-Hahn, J., & Voth, M. (1994). Dynamics of mitochondria in living cells: Shape changes, dislocations, fusion, and fission of mitochondria. Microscopy Research and Technique, 27, 198–219.PubMedGoogle Scholar
  14. Billings, L. M., Oddo, S., Green, K. N., et al. (2005). Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron, 45(5), 675–688.PubMedGoogle Scholar
  15. Blasko, I., Marx, F., Steiner, E., et al. (1999). TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. The FASEB Journal, 13, 63–68.PubMedGoogle Scholar
  16. Blennow, K., & Zetterberg, H. (2009). Cerebrospinal fluid biomarkers for Alzheimer’s disease. Journal of Alzheimer’s Disease, 18, 413–417.PubMedGoogle Scholar
  17. Blurton-Jones, M., & Laferla, F. M. (2006). Pathways by which Abeta facilitates tau pathology. Current Alzheimer Research, 3, 437–448.PubMedGoogle Scholar
  18. Bolmont, T., Clavaguera, F., Meyer-Luehmann, M., et al. (2007). Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. American Journal of Pathology, 171, 2012–2020.PubMedGoogle Scholar
  19. Bolmont, T., Haiss, F., Eicke, D., et al. (2008). Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. Journal of Neuroscience, 28, 4283–4292.PubMedGoogle Scholar
  20. Boncristiano, S., Calhoun, M. E., Howard, V., et al. (2005). Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic mice. Neurobiology of Aging, 26, 607–613.PubMedGoogle Scholar
  21. Borchelt, D. R., Ratovitski, T., van Lare, J., et al. (1997). Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron, 19, 939–945.PubMedGoogle Scholar
  22. Borchelt, D. R., Thinakaran, G., Eckman, C. B., et al. (1996). Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1–42/1–40 ratio in vitro and in vivo. Neuron, 17, 1005–1013.PubMedGoogle Scholar
  23. Brody, D. L., & Holtzman, D. M. (2008). Active and passive immunotherapy for neurodegenerative disorders. Annual Review of Neuroscience, 31, 175–193.PubMedGoogle Scholar
  24. Buxbaum, J. D., Christensen, J. L., Ruefli, A. A., et al. (1993). Expression of APP in brains of transgenic mice containing the entire human APP gene. Biochemical and Biophysical Research Communications, 197, 639–645.PubMedGoogle Scholar
  25. Buxbaum, J. D., Oishi, M., Chen, H. I., et al. (1992). Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proceedings of the National Academy of Sciences of the United States of America, 89, 10075–10078.PubMedGoogle Scholar
  26. Calhoun, M. E., Wiederhold, K. H., Abramowski, D., et al. (1998). Neuron loss in APP transgenic mice. Nature, 395, 755–756.PubMedGoogle Scholar
  27. Casas, C., Sergeant, N., Itier, J. M., et al. (2004). Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. American Journal of Pathology, 165, 1289–1300.PubMedGoogle Scholar
  28. Caspersen, C., Wang, N., Yao, J., et al. (2005). Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. The FASEB Journal, 19, 2040–2041.PubMedGoogle Scholar
  29. Chapman, P. F., White, G. L., Jones, M. W., et al. (1999). Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nature Neuroscience, 2, 271–276.PubMedGoogle Scholar
  30. Chartier-Harlin, M. C., Crawford, F., Houlden, H., et al. (1991). Early-onset Alzheimer’s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature, 353, 844–846.PubMedGoogle Scholar
  31. Chen, W. S., & Bear, M. F. (2007). Activity-dependent regulation of NR2B translation contributes to metaplasticity in mouse visual cortex. Neuropharmacology, 52, 200–214.PubMedGoogle Scholar
  32. Chen, G., Chen, K. S., Knox, J., et al. (2000). A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer’s disease. Nature, 408, 975–979.PubMedGoogle Scholar
  33. Cheng, I. H., Palop, J. J., Esposito, L. A., et al. (2004). Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nature Medicine, 10, 1190–1192.PubMedGoogle Scholar
  34. Cheng, I. H., Scearce-Levie, K., Legleiter, J., et al. (2007). Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. The Journal of Biological Chemistry, 282, 23818–23828.PubMedGoogle Scholar
  35. Chin, J., Palop, J. J., Puolivali, J., et al. (2005). Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer’s disease. Journal of Neuroscience, 25, 9694–9703.PubMedGoogle Scholar
  36. Chishti, M. A., Yang, D. S., Janus, C., et al. (2001). Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. The Journal of Biological Chemistry, 276, 21562–21570.PubMedGoogle Scholar
  37. Choi, J. K., Dedeoglu, A., & Jenkins, B. G. (2007). Application of MRS to mouse models of neurodegenerative illness. NMR in Biomedicine, 20, 216–237.PubMedGoogle Scholar
  38. Chong, Y. (1997). Effect of a carboxy-terminal fragment of the Alzheimer’s amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells. Life Science, 61, 2323–2333.Google Scholar
  39. Chui, D. H., Shirotani, K., Tanahashi, H., et al. (1998). Both N-terminal and C-terminal fragments of presenilin 1 colocalize with neurofibrillary tangles in neurons and dystrophic neurites of senile plaques in Alzheimer’s disease. Journal of Neuroscience Research, 53, 99–106.PubMedGoogle Scholar
  40. Cleary, J. P., Walsh, D. M., Hofmeister, J. J., et al. (2005). Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nature Neuroscience, 8, 79–84.PubMedGoogle Scholar
  41. Comery, T. A., Martone, R. L., Aschmies, S., et al. (2005). Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer’s disease. Journal of Neuroscience, 25, 8898–8902.PubMedGoogle Scholar
  42. Cooke, S. F., & Bliss, T. V. (2006). Plasticity in the human central nervous system. Brain, 129, 1659–1673.PubMedGoogle Scholar
  43. Corcoran, K. A., Lu, Y., Turner, R. S., & Maren, S. (2002). Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer’s disease. Learning & Memory, 9, 243–252.Google Scholar
  44. Cruz, J. C., Kim, D., Moy, L. Y., et al. (2006). p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. Journal of Neuroscience, 26(41), 10536–10541.PubMedGoogle Scholar
  45. Cummings, J. L. (2007). Treatment of Alzheimer’s disease: The role of symptomatic agents in an era of disease-modifying therapies. Reviews in Neurological Diseases, 4, 57–62.PubMedGoogle Scholar
  46. DeKosky, S. T., & Scheff, S. W. (1990). Synapse loss in frontal cortex biopsies in Alzheimer’s disease: Correlation with cognitive severity. Annals of Neurology, 27, 457–464.PubMedGoogle Scholar
  47. Del Bo, R., Angeretti, N., Lucca, E., et al. (1995). Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production in cultures. Neuroscience Letters, 188, 70–74.PubMedGoogle Scholar
  48. Delatour, B., Guegan, M., Volk, A., & Dhenain, M. (2006). In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice. Neurobiology of Aging, 27, 835–847.PubMedGoogle Scholar
  49. Dere, E., Huston, J. P., & De Souza Silva, M. A. (2007). The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neuroscience and Biobehavioral Reviews, 31, 673–704.PubMedGoogle Scholar
  50. Dhenain, M., Privat, N., Duyckaerts, C., et al. (2002). Senile plaques do not induce susceptibility effects in T2*-weighted MR microscopic images. NMR in Biomedicine, 15, 197–203.PubMedGoogle Scholar
  51. Dinamarca, M. C., Arrazola, M., Toledo, E., et al. (2008). Release of acetylcholinesterase (AChE) from beta-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice. Chemico-biological Interactions, 175, 142–149.PubMedGoogle Scholar
  52. Dodart, J. C., Bales, K. R., Gannon, K. S., et al. (2002). Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nature Neuroscience, 5, 452–457.PubMedGoogle Scholar
  53. Dodart, J. C., Mathis, C., Bales, K. R., et al. (2000a). Behavioral deficits in APP(V717F) transgenic mice deficient for the apolipoprotein E gene. Neuroreport, 11, 603–607.PubMedGoogle Scholar
  54. Dodart, J. C., Mathis, C., Saura, J., et al. (2000b). Neuroanatomical abnormalities in behaviorally characterized APP(V717F) transgenic mice. Neurobiology of Diseases, 7, 71–85.Google Scholar
  55. Dodart, J. C., Meziane, H., Mathis, C., et al. (1999). Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behavioral Neuroscience, 113, 982–990.PubMedGoogle Scholar
  56. Dong, J., Revilla-Sanchez, R., Moss, S., et al. (2010) Multiphoton in vivo imaging of amyloid in animal models of Alzheimer’s disease. Neuropharmacology, 1–8.Google Scholar
  57. Du, H., Guo, L., Fang, F., et al. (2008). Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nature Medicine, 14, 1097–1105.PubMedGoogle Scholar
  58. Duff, K., Eckman, C., Zehr, C., et al. (1996). Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature, 383, 710–713.PubMedGoogle Scholar
  59. Duff, K., & Suleman, F. (2004). Transgenic mouse models of Alzheimer’s disease: How useful have they been for therapeutic development? Briefings in Functional Genomics & Proteomics, 3, 47–59.Google Scholar
  60. Esh, C., Patton, L., Kalback, W., et al. (2005). Altered APP processing in PDAPP (Val717–> Phe) transgenic mice yields extended-length Abeta peptides. Biochemistry, 44, 13807–13819.PubMedGoogle Scholar
  61. Espana, J., Gimenez-Llort, L., Valero, J., et al. (2010). Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer’s disease transgenic mice. Biological Psychiatry, 67, 513–521.PubMedGoogle Scholar
  62. Fagan, A. M., Mintun, M. A., Mach, R. H., et al. (2006). Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Annals of Neurology, 59, 512–519.PubMedGoogle Scholar
  63. Falangola, M. F., Lee, S. P., Nixon, R. A., et al. (2005). Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochemical Research, 30, 201–205.PubMedGoogle Scholar
  64. Forloni, G., Demicheli, F., Giorgi, S., et al. (1992). Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: Modulation by interleukin-1. Brain Research. Molecular Brain Research, 16(1–2), 128–134.PubMedGoogle Scholar
  65. Forloni, G., Lucca, E., Angeretti, N., et al. (1997). Amidation of beta-amyloid peptide strongly reduced the amyloidogenic activity without alteration of the neurotoxicity. Journal of Neurochemistry, 69(5), 2048–2054.PubMedGoogle Scholar
  66. Frisoni, G. B., Fox, N. C., Jack, C. R., et al. (2010). The clinical use of structural MRI in Alzheimer disease. Nature Reviews. Neurology, 6, 67–77.PubMedGoogle Scholar
  67. Funato, H., Enya, M., Yoshimura, M., et al. (1999). Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. American Journal of Pathology, 155, 23–28.PubMedGoogle Scholar
  68. Games, D., Adams, D., Alessandrini, R., et al. (1995). Alzheimer-type neuropathology in transgenic mice over-expressing V717F beta-amyloid precursor protein. Nature, 373, 523–527.PubMedGoogle Scholar
  69. Garcia-Alloza, M., & Bacskai, B. J. (2004). Techniques for brain imaging in vivo. Neuromolecular Medicine, 6, 65–78.PubMedGoogle Scholar
  70. Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., et al. (2006). Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiology of Diseases, 24, 516–524.Google Scholar
  71. Gilman, S., Koller, M., Black, R. S., et al. (2005). Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 64, 1553–1562.PubMedGoogle Scholar
  72. Gitter, B. D., Cox, L. M., Rydel, R. E., et al. (1995). Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells. Proceedings of the National Academy of Sciences of the United States of America, 92, 10738–10741.PubMedGoogle Scholar
  73. Glenner, G. G., & Wong, C. W. (1984). Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and Biophysical Research Communications, 120, 885–890.PubMedGoogle Scholar
  74. Goate, A., Chartier-Harlin, M. C., Mullan, M., et al. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature, 349, 704–706.PubMedGoogle Scholar
  75. Gonzalez-Lima, F., Berndt, J. D., Valla, J. E., et al. (2001). Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer’s disease. Neuroreport, 12, 2375–2379.PubMedGoogle Scholar
  76. Gordon, M. N., King, D. L., Diamond, D. M., et al. (2001). Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiology of Aging, 22, 377–385.PubMedGoogle Scholar
  77. Gotz, J., Chen, F., van Dorpe, J., et al. (2001). Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science, 293, 1491–1495.PubMedGoogle Scholar
  78. Gotz, J., Schild, A., Hoerndli, F., et al. (2004). Amyloid-induced neurofibrillary tangle formation in Alzheimer’s disease: Insight from transgenic mouse and tissue-culture models. International Journal of Developmental Neuroscience, 22, 453–465.PubMedGoogle Scholar
  79. Gouras, G. K., Tsai, J., Naslund, J., et al. (2000). Intraneuronal Abeta42 accumulation in human brain. American Journal of Pathology, 156, 15–20.PubMedGoogle Scholar
  80. Greco, S. J., Bryan, K. J., Sarkar, S., et al. (2010). Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer’s disease. Journal of Alzheimer’s Disease, 19, 1155–1167.PubMedGoogle Scholar
  81. Grueninger, F., Bohrmann, B., & Czech, C. (2010). Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiology of Diseases, 37(2), 294–306.Google Scholar
  82. Grutzendler, J., Helmin, K., Tsai, J., et al. (2007). Various dendritic abnormalities are associated with fibrillar amyloid deposits in Alzheimer’s disease. Annals of the New York Academy of Sciences, 1097, 30–39.PubMedGoogle Scholar
  83. Guo, J. T., Yu, J., Grass, D., et al. (2002). Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. Journal of Neuroscience, 22, 5900–5909.PubMedGoogle Scholar
  84. Gyure, K. A., Durham, R., Stewart, W. F., et al. (2001). Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Archives of Pathology and Laboratory Medicine, 125, 489–492.PubMedGoogle Scholar
  85. Haass, C., & Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer’s amyloid beta-peptide. Nature Reviews. Molecular Cell Biology, 8, 101–112.PubMedGoogle Scholar
  86. Hampel, H., Broich, K., Hoessler, Y., et al. (2009). Biological markers for early detection and pharmacological treatment of Alzheimer’s disease. Dialogues in Clinical Neuroscience, 11, 141–157.PubMedGoogle Scholar
  87. Hardy, J. A., & Higgins, G. A. (1992). Alzheimer’s disease: The amyloid cascade hypothesis. Science, 256, 184–185.PubMedGoogle Scholar
  88. Hardy, J., & Orr, H. (2006). The genetics of neurodegenerative diseases. Journal of Neurochemistry, 97, 1690–1699.PubMedGoogle Scholar
  89. Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science, 297, 353–356.PubMedGoogle Scholar
  90. Hauptmann, S., Scherping, I., Drose, S., et al. (2009). Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiology of Aging, 30, 1574–1586.PubMedGoogle Scholar
  91. Herzig, M. C., Winkler, D. T., Burgermeister, P., et al. (2004). Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nature Neuroscience, 7, 954–960.PubMedGoogle Scholar
  92. Hirai, K., Aliev, G., Nunomura, A., et al. (2001). Mitochondrial abnormalities in Alzheimer’s disease. Journal of Neuroscience, 21, 3017–3023.PubMedGoogle Scholar
  93. Hirose, Y., Imai, Y., Nakajima, K., et al. (1994). Glial conditioned medium alters the expression of amyloid precursor protein in SH-SY5Y neuroblastoma cells. Biochemical and Biophysical Research Communications, 198, 504–509.PubMedGoogle Scholar
  94. Holcomb, L., Gordon, M. N., McGowan, E., et al. (1998). Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Medicine, 4, 97–100.PubMedGoogle Scholar
  95. Holmes, C., Boche, D., Wilkinson, D., et al. (2008). Long-term effects of Abeta42 immunisation in Alzheimer’s disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet, 372, 216–223.PubMedGoogle Scholar
  96. Howlett, D. R., Bowler, K., Soden, P. E., et al. (2008). Abeta deposition and related pathology in an APP × PS1 transgenic mouse model of Alzheimer’s disease. Histology and Histopathology, 23, 67–76.PubMedGoogle Scholar
  97. Howlett, D. R., Richardson, J. C., Austin, A., et al. (2004). Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Research, 1017, 130–136.PubMedGoogle Scholar
  98. Hsia, A. Y., Masliah, E., McConlogue, L., et al. (1999). Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proceedings of the National Academy of Sciences of the United States of America, 96, 3228–3233.PubMedGoogle Scholar
  99. Hsiao, K. K., Borchelt, D. R., Olson, K., et al. (1995). Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron, 15, 1203–1218.PubMedGoogle Scholar
  100. Hsiao, K., Chapman, P., Nilsen, S., et al. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science, 274, 99–102.PubMedGoogle Scholar
  101. Hughes, R. N. (2004). The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neuroscience and Biobehavioral Reviews, 28, 497–505.PubMedGoogle Scholar
  102. Hussain, I. (2010). APP transgenic mouse models and their use in drug discovery to evaluate amyloid-b lowering therapeutics. CNS & Neurological Disorders Drug Targets, 9, 395–402.Google Scholar
  103. Imbimbo, B. P. (2008). Therapeutic potential of gamma-secretase inhibitors and modulators. Current Topics in Medicinal Chemistry, 8, 54–61.PubMedGoogle Scholar
  104. Irizarry, M. C., McNamara, M., Fedorchak, K., et al. (1997a). APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. Journal of Neuropathology and Experimental Neurology, 56, 965–973.PubMedGoogle Scholar
  105. Irizarry, M. C., Soriano, F., McNamara, M., et al. (1997b). Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. Journal of Neuroscience, 17, 7053–7059.PubMedGoogle Scholar
  106. Jack, C. R., Jr., Garwood, M., Wengenack, T. M., et al. (2004). In vivo visualization of Alzheimer’s amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magnetic Resonance in Medicine, 52, 1263–1271.PubMedGoogle Scholar
  107. Jack, C. R., Jr., Marjanska, M., Wengenack, T. M., et al. (2007). Magnetic resonance imaging of Alzheimer’s pathology in the brains of living transgenic mice: A new tool in Alzheimer’s disease research. Neuroscientist, 13, 38–48.PubMedGoogle Scholar
  108. Jack, C. R., Jr., Wengenack, T. M., Reyes, D. A., et al. (2005). In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer’s transgenic mice. Journal of Neuroscience, 25, 10041–10048.PubMedGoogle Scholar
  109. Jacobsen, J. S., Wu, C. C., Redwine, J. M., et al. (2006). Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America, 103, 5161–5166.PubMedGoogle Scholar
  110. Janus, C., Pearson, J., McLaurin, J., et al. (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature, 408, 979–982.PubMedGoogle Scholar
  111. Jarrett, J. T., Berger, E. P., & Lansbury, P. T., Jr. (1993). The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer’s disease. Biochemistry, 32, 4693–4697.PubMedGoogle Scholar
  112. Jonas, E. (2006). BCL-xL regulates synaptic plasticity. Molecular Interventions, 6, 208–222.PubMedGoogle Scholar
  113. Kalback, W., Watson, M. D., Kokjohn, T. A., et al. (2002). APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer’s disease senile plaques. Biochemistry, 41, 922–928.PubMedGoogle Scholar
  114. Kamenetz, F., Tomita, T., Hsieh, H., et al. (2003). APP processing and synaptic function. Neuron, 37, 925–937.PubMedGoogle Scholar
  115. Kelly, P. H., Bondolfi, L., Hunziker, D., et al. (2003). Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiology of Aging, 24, 365–378.PubMedGoogle Scholar
  116. Khlistunova, I., Biernat, J., Wang, Y., et al. (2006). Inducible expression of Tau repeat domain in cell models of tauopathy: Aggregation is toxic to cells but can be reversed by inhibitor drugs. The Journal of Biological Chemistry, 281, 1205–1214.PubMedGoogle Scholar
  117. Killiany, R. J., Gomez-Isla, T., Moss, M., et al. (2000). Use of structural magnetic resonance imaging to predict who will get Alzheimer’s disease. Annals of Neurology, 47, 430–439.PubMedGoogle Scholar
  118. Kitazawa, M., Oddo, S., Yamasaki, T. R., et al. (2005). Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease. Journal of Neuroscience, 25, 8843–8853.PubMedGoogle Scholar
  119. Klein, W. L., Krafft, G. A., & Finch, C. E. (2001). Targeting small Abeta oligomers: The solution to an Alzheimer’s disease conundrum? Trends in Neurosciences, 24, 219–224.PubMedGoogle Scholar
  120. Klunk, W. E., Bacskai, B. J., Mathis, C. A., et al. (2002). Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. Journal of Neuropathology and Experimental Neurology, 61, 797–805.PubMedGoogle Scholar
  121. Klunk, W. E., Lopresti, B. J., Ikonomovic, M. D., et al. (2005). Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer’s disease brain but not in transgenic mouse brain. Journal of Neuroscience, 25, 10598–10606.PubMedGoogle Scholar
  122. Klunk, W. E., Wang, Y., Huang, G. F., et al. (2003). The binding of 2-(4’-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. Journal of Neuroscience, 23, 2086–2092.PubMedGoogle Scholar
  123. Klyubin, I., Betts, V., Welzel, A. T., et al. (2008). Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: Prevention by systemic passive immunization. Journal of Neuroscience, 28, 4231–4237.PubMedGoogle Scholar
  124. Knobloch, M., Konietzko, U., Krebs, D. C., et al. (2007). Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiology of Aging, 28, 1297–1306.PubMedGoogle Scholar
  125. Kobayashi, D. T., & Chen, K. S. (2005). Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer’s disease. Genes, Brain, and Behavior, 4, 173–196.PubMedGoogle Scholar
  126. Kotilinek, L. A., Bacskai, B., Westerman, M., et al. (2002). Reversible memory loss in a mouse transgenic model of Alzheimer’s disease. Journal of Neuroscience, 22, 6331–6335.PubMedGoogle Scholar
  127. Kuo, Y. M., Beach, T. G., Sue, L. I., et al. (2001a). The evolution of A beta peptide burden in the APP23 transgenic mice: Implications for A beta deposition in Alzheimer disease. Molecular Medicine, 7, 609–618.PubMedGoogle Scholar
  128. Kuo, Y. M., Crawford, F., Mullan, M., et al. (2000). Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer’s disease. Molecular Medicine, 6, 430–439.PubMedGoogle Scholar
  129. Kuo, Y. M., Kokjohn, T. A., Beach, T. G., et al. (2001b). Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer’s disease brains. The Journal of Biological Chemistry, 276, 12991–12998.PubMedGoogle Scholar
  130. Kurt, M. A., Davies, D. C., Kidd, M., et al. (2001). Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Experimental Neurology, 171, 59–71.PubMedGoogle Scholar
  131. LaFerla, F. M., Green, K. N., & Oddo, S. (2007). Intracellular amyloid-beta in Alzheimer’s disease. Nature Reviews. Neuroscience, 8, 499–509.PubMedGoogle Scholar
  132. Lalonde, R. (2002). The neurobiological basis of spontaneous alternation. Neuroscience and Biobehavioral Reviews, 26, 91–104.PubMedGoogle Scholar
  133. Lamb, B. T., Sisodia, S. S., Lawler, A. M., et al. (1993). Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected]. Nature Genetics, 5, 22–30.PubMedGoogle Scholar
  134. Langui, D., Girardot, N., El Hachimi, K. H., et al. (2004). Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. American Journal of Pathology, 165, 1465–1477.PubMedGoogle Scholar
  135. Larson, J., Lynch, G., Games, D., et al. (1999). Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Research, 840, 23–35.PubMedGoogle Scholar
  136. Lau, J. C., Lerch, J. P., Sled, J. G., et al. (2008). Longitudinal neuroanatomical changes determined by deformation-based morphometry in a mouse model of Alzheimer’s disease. Neuroimage, 42, 19–27.PubMedGoogle Scholar
  137. Lee, M. K., Borchelt, D. R., Kim, G., et al. (1997). Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nature Medicine, 3, 756–760.PubMedGoogle Scholar
  138. Lee, S. P., Falangola, M. F., Nixon, R. A., et al. (2004). Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer’s disease using MR microscopy without contrast reagents. Magnetic Resonance in Medicine, 52, 538–544.PubMedGoogle Scholar
  139. Lee, J. W., Lee, Y. K., Yuk, D. Y., et al. (2008). Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. Journal of Neuroinflammation, 5, 37.PubMedGoogle Scholar
  140. Lehman, E. J., Kulnane, L. S., Gao, Y., et al. (2003). Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Human Molecular Genetics, 12, 2949–2956.PubMedGoogle Scholar
  141. Lesne, S., Koh, M. T., Kotilinek, L., et al. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. Nature, 440, 352–357.PubMedGoogle Scholar
  142. Lovasic, L., Bauschke, H., & Janus, C. (2005). Working memory impairment in a transgenic amyloid precursor protein TgCRND8 mouse model of Alzheimer’s disease. Genes, Brain, and Behavior, 4, 197–208.PubMedGoogle Scholar
  143. Lue, L. F., Kuo, Y. M., Roher, A. E., et al. (1999). Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. American Journal of Pathology, 155, 853–862.PubMedGoogle Scholar
  144. Lustbader, J. W., Cirilli, M., Lin, C., et al. (2004). ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science, 304, 448–452.PubMedGoogle Scholar
  145. Maeda, J., Ji, B., Irie, T., et al. (2007). Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer’s disease enabled by positron emission tomography. Journal of Neuroscience, 27, 10957–10968.PubMedGoogle Scholar
  146. Maheswaran, S., Barjat, H., Rueckert, D., et al. (2009). Longitudinal regional brain volume changes quantified in normal aging and Alzheimer’s APP × PS1 mice using MRI. Brain Research, 1270, 19–32.PubMedGoogle Scholar
  147. Manczak, M., Anekonda, T. S., Henson, E., et al. (2006). Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression. Human Molecular Genetics, 15, 1437–1449.PubMedGoogle Scholar
  148. Masliah, E., Sisk, A., Mallory, M., & Games, D. (2001). Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Journal of Neuropathology and Experimental Neurology, 60, 357–368.PubMedGoogle Scholar
  149. Masters, C. L., Simms, G., Weinman, N. A., et al. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences of the United States of America, 82, 4245–4249.PubMedGoogle Scholar
  150. Mattson, M. P. (2004). Pathways towards and away from Alzheimer’s disease. Nature, 430, 631–639.PubMedGoogle Scholar
  151. Mattson, M. P., Gleichmann, M., & Cheng, A. (2008). Mitochondria in neuroplasticity and neurological disorders. Neuron, 60, 748–766.PubMedGoogle Scholar
  152. Maurer, I., Zierz, S., & Moller, H. J. (2000). A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiology of Aging, 21, 455–462.PubMedGoogle Scholar
  153. McCool, M. F., Varty, G. B., Del Vecchio, R. A., et al. (2003). Increased auditory startle response and reduced prepulse inhibition of startle in transgenic mice expressing a double mutant form of amyloid precursor protein. Brain Research, 994, 99–106.PubMedGoogle Scholar
  154. McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: A review of 17 epidemiologic studies. Neurology, 47, 425–432.PubMedGoogle Scholar
  155. McGowan, E., Sanders, S., Iwatsubo, T., et al. (1999). Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiology of Diseases, 6, 231–244.Google Scholar
  156. McLean, C. A., Cherny, R. A., Fraser, F. W., et al. (1999). Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Annals of Neurology, 46, 860–866.PubMedGoogle Scholar
  157. Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., et al. (2008). Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature, 451, 720–724.PubMedGoogle Scholar
  158. Moechars, D., Dewachter, I., Lorent, K., et al. (1999). Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. The Journal of Biological Chemistry, 274, 6483–6492.PubMedGoogle Scholar
  159. Moran, P. M., Higgins, L. S., Cordell, B., et al. (1995). Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America, 92, 5341–5345.PubMedGoogle Scholar
  160. Morris, R. (1984). Developments of a water-maze procedure for studying spatial learning in the rat. Journal of Neuroscience Methods, 11, 47–60.PubMedGoogle Scholar
  161. Morris, R. G., Garrud, P., Rawlins, J. N., & ET, A. L. (1982). Place navigation impaired in rats with hippocampal lesions. Nature, 297, 681–683.PubMedGoogle Scholar
  162. Mosconi, L., De Santi, S., Li, J., et al. (2008). Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiology of Aging, 29, 676–692.PubMedGoogle Scholar
  163. Mouri, A., Noda, Y., Hara, H., et al. (2007). Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. The FASEB Journal, 21, 2135–2148.PubMedGoogle Scholar
  164. Mucke, L. (2009). Neuroscience: Alzheimer’s disease. Nature, 461, 895–897.PubMedGoogle Scholar
  165. Mucke, L., Masliah, E., Yu, G. Q., et al. (2000). High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. Journal of Neuroscience, 20, 4050–4058.PubMedGoogle Scholar
  166. Mullan, M., Crawford, F., Axelman, K., et al. (1992). A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of beta-amyloid. Nature Genetics, 1, 345–347.PubMedGoogle Scholar
  167. Murrell, J., Farlow, M., Ghetti, B., et al. (1991). A mutation in the amyloid precursor protein associated with hereditary Alzheimer’s disease. Science, 254, 97–99.PubMedGoogle Scholar
  168. Nabeshi, H., Oikawa, S., Inoue, S., et al. (2006). Proteomic analysis for protein carbonyl as an indicator of oxidative damage in senescence-accelerated mice. Free Radical Research, 40, 1173–1181.PubMedGoogle Scholar
  169. Naslund, J., Haroutunian, V., Mohs, R., et al. (2000). Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA, 283, 1571–1577.PubMedGoogle Scholar
  170. Neff, F., Wei, X., Nolker, C., et al. (2008). Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmunity Reviews, 7, 501–507.PubMedGoogle Scholar
  171. Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., et al. (2001). The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nature Neuroscience, 4, 887–893.PubMedGoogle Scholar
  172. Nordberg, A. (2008). Amyloid plaque imaging in vivo: Current achievement and future prospects. European Journal of Nuclear Medicine and Molecular Imaging 35(suppl 1), S46–S50.Google Scholar
  173. Oakley, H., Cole, S. L., Logan, S., et al. (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. Journal of Neuroscience, 26, 10129–10140.PubMedGoogle Scholar
  174. Oddo, S., Billings, L., Kesslak, J. P., et al. (2004). Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 43, 321–332.PubMedGoogle Scholar
  175. Oddo, S., Caccamo, A., Shepherd, J. D., et al. (2003). Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron, 39, 409–421.PubMedGoogle Scholar
  176. Oddo, S., Caccamo, A., Smith, I. F., et al. (2006a). A dynamic relationship between intracellular and extracellular pools of Abeta. American Journal of Pathology, 168, 184–194.PubMedGoogle Scholar
  177. Oddo, S., Vasilevko, V., Caccamo, A., et al. (2006b). Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. The Journal of Biological Chemistry, 281, 39413–39423.PubMedGoogle Scholar
  178. Olton, D. S. (1987). The radial arm maze as a tool in behavioral pharmacology. Physiology & Behavior, 40, 793–797.Google Scholar
  179. Pallas, M., Camins, A., Smith, M. A., et al. (2008). From aging to Alzheimer’s disease: Unveiling “the switch” with the senescence-accelerated mouse model (SAMP8). Journal of Alzheimer’s Disease, 15, 615–624.PubMedGoogle Scholar
  180. Palop, J. J., Jones, B., Kekonius, L., et al. (2003). Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer’s disease-related cognitive deficits. Proceedings of the National Academy of Sciences of the United States of America, 100, 9572–9577.PubMedGoogle Scholar
  181. Pfeifer, M., Boncristiano, S., Bondolfi, L., et al. (2002). Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science, 298, 1379.PubMedGoogle Scholar
  182. Phillips, R. G., & LeDoux, J. E. (1992). Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behavioral Neuroscience, 106, 274–285.PubMedGoogle Scholar
  183. Pietropaolo, S., Feldon, J., & Yee, B. K. (2008). Age-dependent phenotypic characteristics of a triple transgenic mouse model of Alzheimer disease. Behavioral Neuroscience, 122, 733–747.PubMedGoogle Scholar
  184. Poduslo, J. F., Wengenack, T. M., Curran, G. L., et al. (2002). Molecular targeting of Alzheimer’s amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiology of Diseases, 11, 315–329.Google Scholar
  185. Pype, S., Moechars, D., Dillen, L., et al. (2003). Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein. Journal of Neurochemistry, 84, 602–609.PubMedGoogle Scholar
  186. Querfurth, H. W., & LaFerla, F. M. (2010). Alzheimer’s disease. New England Journal of Medicine, 362, 329–344.PubMedGoogle Scholar
  187. Reaume, A. G., Howland, D. S., Trusko, S. P., et al. (1996). Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer’s disease mutations and a “humanized” Abeta sequence. The Journal of Biological Chemistry, 271, 23380–23388.PubMedGoogle Scholar
  188. Redwine, J. M., Kosofsky, B., Jacobs, R. E., et al. (2003). Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: A magnetic resonance microscopy and stereologic analysis. Proceedings of the National Academy of Sciences of the United States of America, 100, 1381–1386.PubMedGoogle Scholar
  189. Rhein, V., Song, X., & Wiesner, A. (2009). Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice. Proceedings of the National Academy of Sciences of the United States of America, 106(47), 20057–20062.PubMedGoogle Scholar
  190. Rockenstein, E., Mallory, M., Mante, M., et al. (2001). Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1–42). Journal of Neuroscience Research, 66, 573–582.PubMedGoogle Scholar
  191. Rogaev, E. I., Sherrington, R., Rogaeva, E. A., et al. (1995). Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature, 376, 775–778.PubMedGoogle Scholar
  192. Roher, A. E., & Kokjohn, T. A. (2002). Of mice and men: The relevance of transgenic mice Abeta immunizations to Alzheimer’s disease. Journal of Alzheimer’s Disease, 4, 431–434.PubMedGoogle Scholar
  193. Roher, A. E., Palmer, K. C., Capodilupo, J., et al. (1991). New biochemical insights to unravel the pathogenesis of Alzheimer’s lesions. Canadian Journal of Neurological Sciences, 18, 408–410.PubMedGoogle Scholar
  194. Roher, A. E., Palmer, K. C., Yurewicz, E. C., et al. (1993). Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. Journal of Neurochemistry, 61, 1916–1926.PubMedGoogle Scholar
  195. Roskam, S., Neff, F., Schwarting, R., et al. (2010). APP transgenic mice: The effect of active and passive immunotherapy in cognitive tasks. Neuroscience and Biobehavioral Reviews, 34, 487–499.PubMedGoogle Scholar
  196. Rustay, N. R., Cronin, E. A., Curzon, P., et al. (2010). Mice expressing the Swedish APP mutation on a 129 genetic background demonstrate consistent behavioral deficits and pathological markers of Alzheimer’s disease. Brain Research, 1311, 136–147.PubMedGoogle Scholar
  197. Santacruz, K., Lewis, J., Spires, T., et al. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science, 309, 476–481.PubMedGoogle Scholar
  198. Sastre, M., Dewachter, I., Landreth, G. E., et al. (2003). Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. Journal of Neuroscience, 23, 9796–9804.PubMedGoogle Scholar
  199. Schenk, D., Barbour, R., Dunn, W., et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173–177.PubMedGoogle Scholar
  200. Schmitz, C., Rutten, B. P., Pielen, A., et al. (2004). Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer’s disease. American Journal of Pathology, 164, 1495–1502.PubMedGoogle Scholar
  201. Scholtzova, H., Wadghiri, Y. Z., Douadi, M., et al. (2008). Memantine leads to behavioral improvement and amyloid reduction in Alzheimer’s-disease-model transgenic mice shown as by micromagnetic resonance imaging. Journal of Neuroscience Research, 86, 2784–2791.PubMedGoogle Scholar
  202. Selkoe, D. J. (2008). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behavioural Brain Research, 192, 106–113.PubMedGoogle Scholar
  203. Shankar, G. M., Li, S., Mehta, T. H., et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nature Medicine, 14, 837–842.PubMedGoogle Scholar
  204. Sherrington, R., Rogaev, E. I., Liang, Y., et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature, 375, 754–760.PubMedGoogle Scholar
  205. Slangen, J. L., Earley, B., Jaffard, R., et al. (1990). Behavioral models of memory and amnesia. Pharmacopsychiatry, 23(Suppl 2), 81–83. (discussion 84).Google Scholar
  206. Snyder, E. M., Nong, Y., Almeida, C. G., et al. (2005). Regulation of NMDA receptor trafficking by amyloid-beta. Nature Neuroscience, 8, 1051–1058.PubMedGoogle Scholar
  207. Spires, T. L., Meyer-Luehmann, M., Stern, E. A., et al. (2005). Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. Journal of Neuroscience, 25, 7278–7287.PubMedGoogle Scholar
  208. Squire, L. R., Wixted, J. T., & Clark, R. E. (2007). Recognition memory and the medial temporal lobe: A new perspective. Nature Reviews. Neuroscience, 8, 872–883.PubMedGoogle Scholar
  209. Steele, M., Stuchbury, G., & Munch, G. (2007). The molecular basis of the prevention of Alzheimer’s disease through healthy nutrition. Experimental Gerontology, 42, 28–36.PubMedGoogle Scholar
  210. Sturchler-Pierrat, C., Abramowski, D., Duke, M., et al. (1997). Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proceedings of the National Academy of Sciences of the United States of America, 94, 13287–13292.PubMedGoogle Scholar
  211. Takahashi, R. H., Almeida, C. G., Kearney, P. F., et al. (2004). Oligomerization of Alzheimer’s beta-amyloid within processes and synapses of cultured neurons and brain. Journal of Neuroscience, 24, 3592–3599.PubMedGoogle Scholar
  212. Takahashi, R. H., Milner, T. A., Li, F., et al. (2002). Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. American Journal of Pathology, 161, 1869–1879.PubMedGoogle Scholar
  213. Terry, R. D., Masliah, E., Salmon, D. P., et al. (1991). Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Annals of Neurology, 30, 572–580.PubMedGoogle Scholar
  214. Townsend, M., Shankar, G. M., Mehta, T., et al. (2006). Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: A potent role for trimers. Journal of Physiology, 572, 477–492.PubMedGoogle Scholar
  215. Trinchese, F., Fa, M., Liu, S., et al. (2008). Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. Journal of Clinical Investigation, 118, 2796–2807.PubMedGoogle Scholar
  216. Van Broeck, B., Vanhoutte, G., Cuijt, I., et al. (2008a). Reduced brain volumes in mice expressing APP-Austrian mutation but not in mice expressing APP-Swedish-Austrian mutations. Neuroscience Letters, 447, 143–147.PubMedGoogle Scholar
  217. Van Broeck, B., Vanhoutte, G., Pirici, D., et al. (2008b). Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer’s disease. Neurobiology of Aging, 29, 241–252.PubMedGoogle Scholar
  218. Van Dam, D., D’Hooge, R., Staufenbiel, M., et al. (2003). Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. European Journal of Neuroscience, 17, 388–396.PubMedGoogle Scholar
  219. Van Dam, D., & De Deyn, P. P. (2006). Drug discovery in dementia: The role of rodent models. Nature Reviews. Drug Discovery, 5, 956–970.PubMedGoogle Scholar
  220. Vanhoutte, G., Dewachter, I., Borghgraef, P., et al. (2005). Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer’s disease. Magnetic Resonance in Medicine, 53, 607–613.PubMedGoogle Scholar
  221. Walsh, D. M., Klyubin, I., Fadeeva, J. V., et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416, 535–539.PubMedGoogle Scholar
  222. Walsh, D. M., & Selkoe, D. J. (2007). A beta oligomers - a decade of discovery. Journal of Neurochemistry, 101, 1172–1184.PubMedGoogle Scholar
  223. Webster, S. D., Tenner, A. J., Poulos, T. L., et al. (1999). The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation. Neurobiology of Aging, 20, 297–304.PubMedGoogle Scholar
  224. Wegenast-Braun, B. M., Fulgencio Maisch, A., Eicke, D., et al. (2009). Independent effects of intra- and extracellular Abeta on learning-related gene expression. American Journal of Pathology, 175, 271–282.PubMedGoogle Scholar
  225. Weiss, C., Venkatasubramanian, P. N., Aguado, A. S., et al. (2002). Impaired eyeblink conditioning and decreased hippocampal volume in PDAPP V717F mice. Neurobiology of Diseases, 11, 425–433.Google Scholar
  226. Wengenack, T.M., Jack, C.R., Jr., Garwood, M., et al. (2008). MR microimaging of amyloid plaques in Alzheimer’s disease transgenic mice. European Journal of Nuclear Medicine and Molecular Imaging, 35(Suppl 1), S82–S88.Google Scholar
  227. Westerman, M. A., Cooper-Blacketer, D., Mariash, A., et al. (2002). The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer’s disease. Journal of Neuroscience, 22, 1858–1867.PubMedGoogle Scholar
  228. Wilcock, D. M., Rojiani, A., Rosenthal, A., et al. (2004). Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. Journal of Neuroscience, 24, 6144–6151.PubMedGoogle Scholar
  229. Wirths, O., Multhaup, G., Czech, C., et al. (2001). Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neuroscience Letters, 306, 116–120.PubMedGoogle Scholar
  230. Wu, C. C., Chawla, F., Games, D., et al. (2004). Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: Digital morphometric analyses. Proceedings of the National Academy of Sciences of the United States of America, 101, 7141–7146.PubMedGoogle Scholar
  231. Wyss-Coray, T., & Mucke, L. (2002). Inflammation in neurodegenerative disease–a double-edged sword. Neuron, 35, 419–432.PubMedGoogle Scholar
  232. Yamaguchi, F., Richards, S. J., Beyreuther, K., et al. (1991). Transgenic mice for the amyloid precursor protein 695 isoform have impaired spatial memory. Neuroreport, 2, 781–784.PubMedGoogle Scholar
  233. Yamin, G. (2009). NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. Journal of Neuroscience Research, 87, 1729–1736.PubMedGoogle Scholar
  234. Yao, J., Irwin, R. W., Zhao, L., et al. (2009). Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America, 106, 14670–14675.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of NeuroscienceMario Negri Institute for Pharmacological ResearchMilanItaly

Personalised recommendations